Key result
New thrombosis in lupus anticoagulant-positive patients linked to ~495% higher mortality.
Why the study?
Data on the clinical course and mortality rates of lupus anticoagulant-positive individuals with or without thrombotic or pregnancy complications are limited.
Does the occurrence of a thrombotic event increase mortality in lupus anticoagulant-positive individuals?
Population
151 lupus anticoagulant-positive individuals, 82% female
Comparison
Age-, sex-, and study-inclusion-year-matched Austrian reference population
Design
Prospective observational cohort study
Follow-up
Median 8.2 years
Authors
Loading...
May support closer monitoring after thrombosis in lupus anticoagulant-positive patients; hypothesis-generating for prevention trials.
Observational (n=151)
Does the occurrence of a thrombotic event increase mortality in lupus anticoagulant-positive individuals?
Hazard Ratio: 5.95 (95% CI 2.43–14.95)
In patients with lupus anticoagulant, the occurrence of a new thrombotic event is a strong predictor of increased mortality, suggesting that preventing thromboembolism may improve survival.
Gebhart et al. (2015) conducted an observational in Lupus anticoagulant (LA)-positive (n=151). New onset of thrombosis vs. No new onset of thrombosis was evaluated on Mortality (HR 5.95, 95% CI 2.43-14.95). New onset of thrombosis in lupus anticoagulant-positive patients was strongly associated with increased mortality after multivariable adjustment (HR 5.95; 95% CI 2.43-14.95).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: